- Mar. 4, 2014 - NEEDHAM, Mass. --
Cambridge Healthtech Institute (CHI) recently spoke with Genentech’s Jason Burch, Ph.D., about why he chose to pursue ITK inhibitors, important considerations for developing these types of inhibitors, and what techniques were used to improve pharmaceutical properties of the lead matter. Dr. Burch also discusses how advances in genomics and demand for personalized treatments has changed drug design techniques.LISTEN TO PODCAST BY COPY/PASTING THIS URL INTO YOUR BROWSER:
Dr. Burch is presenting at the 14th Annual “Structure-
Based Drug Design” conference to be held on May 21-22, 2014 at the Westin Boston Waterfront, Boston, MA. Dr. Burch will speak about structure-based design and property optimization of potent and selective pyrazole carboxamide interleukin-
2 inducible t-cell kinase (itk) inhibitors for the treatment of inflammatory diseases.
For more information about the conference, visit www.healthtech.com/structure-based-drug-design
About Cambridge Healthtech Institute
Cambridge Healthtech Institute (CHI), founded in 1992, is the industry leader in providing superior quality scientific information to eminent researchers and business experts from top pharmaceutical, biotech, and academic organizations. Delivering an assortment of resources such as events, reports, publications and eNewsletters, CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners, Cambridge Healthtech Media Group, and The Knowledge Foundation.www.chicorporate.com